Arterial hypertension in adults. Clinical guidelines 2020

Arterial hypertension in adults. Clinical guidelines 2020

1. Sackett DL, Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996 Jan 13;312(7023):71-2.

2. Federal law No. 323-FZ of 21.11.2011 (ed. of 03.04.2017). On the basis of public health protection in the Russian Federation. (In Russ.)

3. Epidemiological dictionary, 4th edition. Edited by John M. last for the International epidemiological Association. Moscow, 2009. p. 316. (In Russ.)

4. Federal Agency for technical regulation and Metrology. National standard of the Russian Federation. GOSTR 52379-2005. Good clinical practice. Moscow, 2005. (In Russ.)

5. Federal law of 12.04.2010 № 61-FZ (03.07.2016) On circulation of medicines. (In Russ.)

6. Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Int Med. 1995;122(4):286-95.

7. Small medical encyclopedia. Moscow: Medical encyclopedia, 1991-96. (In Russ.) http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.

8. Andreeva NS, Rebrova OYu, Zorin NA, et al. Systems for evaluating the reliability of scientific evidence and the credibility of recommendations: comparative characteristics and prospects for unification. Medical technology. Evaluation and selection. 2012;4:10-24. (In Russ.)

9. All-Russian public organization “Russian Association of gerontologists and geriatricians”. Clinical recommendations “Senile asthenia”. 2018. (In Russ.) http://uzrf.ru/userfiles/file/rokgvv/GeriatricCenter/01-1-astenia_recomend.pdf

10. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1•25 million people. Lancet. 2014 May 31;383(9932):1899-911. doi:10.1016/S0140-6736(14)60685-1.

11. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34:951-61.

12. Elliott P, Stamler J, Nichols R, et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ. 1996;312:1249-53.

13. Kushakovsky MS. Essential hypertension (hypertension). The causes, mechanisms, clinical features, treatment. SPb., 2002. (In Russ.)

14. Lang GF. Hypertension. Moscow: Medgiz, 1950. p. 459. (In Russ.)

15. Postnov YuV, Orlov SN. Primary hypertension as a pathology of cell membranes. Moscow: Meditsina, 1987. p. 192. (In Russ.)

16. Myasnikov AL. Hypertension. Moscow: Medgiz, 1954. (In Russ.)

17. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVDRF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.

18. Boytsov SA, Balanova YA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.

19. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.

20. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:243-50.

21. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041.

22. Chazova IE, Zhernakova YuV. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. (In Russ.) doi:10.26442/2075082X.2019.1.190179.

23. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.

24. Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Eur Heart J Cardiovasc Pharmacother. 2017;3:235-50.

25. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA. Neurol. 2017;74:1246-54.

26. Rovio SP, Pahkala K, Nevalainen J, et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J Am Coll Cardiol. 2017;69:2279-89.

27. Vishram JK, Borglykke A, Andreasen AH, et al, MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension. 2012;60:1117-23.

28. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens. 2007;20:338-41.

29. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100:354-60.

30. Domanski M, Mitchell G, Pfeffer M, et al, MRFIT Research Group. Pulse pressure and cardiovascular disease–related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;287:2677-83.

31. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;(12):131-42. (In Russ.) doi:10.15829/1560-40712018-12-131-142.

32. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.

33. Reino-Gonzalez S, Pita-Fernandez S, Seoane-Pillado T, et al. How in-office and ambulatory BP monitoring compare: A systematic review and meta-analysis. J Fam Pract. 2017 Jan;66(1):E5-E12.

34. Kollias A, Ntineri A, Stergiou GS. Association of night-time home blood pressure with nighttime ambulatory blood pressure and target-organ damage: a systematic review and metaanalysis. J Hypertens. 2017 Mar;35(3):442-52. doi: 10.1097/HJH.0000000000001189.

35. Fagard RH, Celis H, Thijs L, et al. Daytime and night–time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61.

36. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449-56.

37. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension. 2006;47:846-53.

38. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens. 2007;25:2193-219.

39. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35:1245-54.

40. Albasri A, OʼSullivan JW, Roberts NW, et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017 Oct;35(10):1919-1928. doi:10.1097/HJH.0000000000001443.

41. Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379:905-14.

42. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-83.

43. Shi Y, Zhou W, Liu X, et al. Resting heart rate and the risk of hypertension and heart failure: a dose-response meta-analysis of prospective studies. J Hypertens. 2018 May;36(5):9951004. doi:10.1097/HJH.0000000000001627.

44. Salles GF, Reboldi G, Fagard RH, et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis. Hypertension. 2016;67:693-700.

45. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449-56.

46. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med. 2017;14:e1002389.

47. Parati G, Stergiou G, O’Brien E, et al, European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359-66.

48. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010;31:883-91.

49. Volpe M, Battistoni A, Tocci G, et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens. 2012;30:1056-64.

50. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003.

51. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis. 1986;39:809-21.

52. Friedman GD, Selby JV, Quesenberry CP Jr, et al Precursors of essential hypertension: body weight, alcohol and salt use and parental history of hypertension. Prev Med 1988;17:387-402.

53. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov I. I., Shestakova M. V., Mayorov A. Yu. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. (In Russ.)

54. Cosentino F, Grant P, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020 Jan 7;41(2):255-323. doi:10.1093/eurheartj/ehz486.

55. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi:10.1016/S0140-6736(10)60484-9.

56. Wilson PW, Cupples CF, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Amer. Heart J. 1991;121:586-90.

57. Izzo R, de Simone G, Trimarco V, et al. Hypertensive target organ damage predicts incident diabetes mellitus. Eur Heart J. 2013 Nov;34(44):3419-26. doi:10.1093/eurheartj/eht281.

58. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD–EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012 May 9;307(18):1941-51. doi:10.1001/jama.2012.3954.

59. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.

60. De Haan MW, Kroon AA, Flobbe K, et al. Renovascular disease in patients with hypertension: detection with duplex ultrasound. J Hum Hypertens. 2002 Jul;16(7):501-7.

61. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1649-61. doi:10.1016/S0140-6736(12)61272-0.

62. Van Der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011 Jun;79(12):1341-52. doi:10.1038/ki.2010.536.

63. Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012;156:785-95.

64. Zachrisson K, Herlitz H, Lonn L, et al. Duplex ultrasound for identifying renal artery stenosis: direct criteria re-evaluated. Acta Radiol. 2017 Feb;58(2):176-82. doi:10.1177/0284185116641345.

65. Matsushita K, Coresh J, Sang Y, et al. Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25. doi:10.1016/S2213-8587(15)00040-6.

66. Gerstein HC, Mann JF, Yi Q, Zinman B, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-6.

67. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012 Mar 28;307(12):1302-9. doi:10.1001/jama.2012.366.

68. Guo X, Zou L, Zhang X, et al. Prehypertension: a meta-analysis of the epidemiology, risk factors, and predictors of progression. Tex Heart Inst J. 2011;38(6):643-52.

69. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens. 2003 Jul;17(7):471-80.

70. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004 Jan 21;43(2):155-61.

71. Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014 Dec 1;9(12):e114259. doi:10.1371/journal.pone.0114259.

72. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta‐analysis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10210. doi:10.1002/acr.20344.

73. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013 Jul 18;347:f4262. doi:10.1136/bmj.f4262.

74. Schillaci G, Battista F, Pucci G. A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. Journal of electrocardiology. 2012;45(6):617-23.

75. Kahn S, Frishman WH, Weissman S, et al. Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc. 1996;44:524-9.

76. Lonn E, Mathew J, Pogue J, et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur J Cardiovasc Prevent Rehab. 2003;10:420-8.

77. Bacharova L, Schocken D, Estes EH, Strauss D. The role of ECG in the diagnosis of left ventricular hypertrophy. Curr Cardiol Rev. 2014;10:257-61.

78. Lehtonen AO, Puukka P, Varis J, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens. 2016;34:959-66.

79. Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.

80. Vanezis AP, Bhopal R. Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. Journal of Electrocardiology. 2008;41(5):404-12.

81. Verdecchia P, Angeli F, Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension. 2003;16(11):895-9.

82. Sundstrom J, Lind L, Arnlov J et al. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001;103:2346-51.

83. Palmieri V, Dahlof B, DeQuattro V et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999;34:1625-32.

84. Levy D, Garrison RJ, Savage DO et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.

85. Perrone-Filardi P, Coca A, Galderisi M, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging. 2017;18:945-60.

86. Mourad JJ, Cacoub P, Collet JP, et al. Screening of unrecognized peripheral arterial disease (PAD) using ankle–brachial index in high cardiovascular risk patients free from symptomatic PAD. J Vasc Surg. 2009 Sep;50(3):572-80. doi:10.1016/j.jvs.2009.04.055.

87. Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, et al. Prediction of Cardiovascular Events and All-Cause Mortality With Brachial-Ankle Elasticity Index: A Systematic Review and Meta-Analysis. Hypertension. 2012;60(2):556-62.

88. Breslin DJ, Gifford RW Jr, Fairbairn JF II, Kearns TP. Prognostic importance of ophthalmoscopic findings in essential hypertension. JAMA. 1966;195:335-8.

89. Fuchs FD, Maestri MK, Bredemeier M, et al. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting. Journal of human hypertension. J Hum Hypertens. 1995 Jul;9(7):547-51.

90. Dimmitt SB, West JN, Eames SM, et al. Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet. 1989;1:1103-6.

91. White PM, Wardlaw JM, Easton V. Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review. Radiology. 2000;217(2):361-70.

92. Beynon R, Sterne JA, Wilcock G, et al. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol. 2012 Jun 6;12:33. doi:10.1186/1471-2377-12-33.

93. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016 Jan 13;(1):CD011145. doi:10.1002/14651858.CD011145.pub2.

94. Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175:1450-8.

95. Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020 Jan 1;41(1):111-188. doi:10.1093/eurheartj/ehz455.

96. Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. Journal of Public Health. 1998;20(4):441-8.

97. Sundstrom J, Arima H, Jackson R, et al. Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162:184-91.

98. Task FM, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-381.

99. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150-60.

100. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.

101. Thijs L, Fagard R, Lijnen P, et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens. 1992 Oct;10(10):1103-9. doi:10.1097/00004872-199210000-00001.

102. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. HOPE-3 Investigators. Blood–pressure lowering in. Intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-20.

103. Williamson JD, Supiano MA, Applegate WB, et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >75 years: a randomized clinical trial. JAMA. 2016;315:2673-82.

104. Beckett N, Peters R, Leonetti G, et al, HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens. 2014;32:1478-87.

105. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-95.

106. Patel A, MacMahon S, Chalmers J, et al, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 Sep 8;370(9590):829-40.

107. Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC cardiovascular disorders. BMC Cardiovasc Disord. 2014 Oct 25;14:148. doi:10.1186/1471-2261-14-148.

108. Garrison SR, Kolber MR, Korownyk CS, et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev. 2017 Aug 8;8:CD011575. doi:10.1002/14651858.CD011575.pub2.

109. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903-13.

110. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613-22.

111. Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226-37.

112. Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25:83-92.

113. Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on– treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37:955-64.

114. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24:215-33.

115. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2224-60. doi:10.1016/S0140-6736(12)61766-8.

116. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013;4:CD004937.

117. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1-15.

118. Taylor RS, Ashton KE, Moxham T, et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens. 2011;24:843-53.

119. Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013;346:f1326.

120. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension. 2001 Nov;38(5):1112-7.

121. Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials. Hypertension. 2016 Apr;67(4):733-9. doi:10.1161/HYPERTENSIONAHA.115.06853.

122. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension. 2003;42:878-84.

123. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.

124. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9. doi:10.1056/NEJMoa1000367.

125. Leitzmann MF, Park Y, Blair A, et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med. 2007 Dec 10;167(22):2453-60.

126. Rossi A, Dikareva A, Bacon SL, Daskalopoulou SS. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens. 2012 Jul;30(7):1277-88. doi:10.1097/HJH.0b013e3283544669.

127. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989 Mar 25;298(6676):789-94.

128. He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease — a meta-analysis of epidemiologic studies. N Engl J Med. 1999 Mar 25;340(12):920-6.

129. Linneberg A, Jacobsen RK, Skaaby T, et al. Effect of smoking on blood pressure and resting heart rate: a mendelian randomization meta-analysis in the CARTA Consortium. Circ Cardiovasc Genet. 2015 Dec;8(6):832-41. doi:10.1161/CIRCGENETICS.115.001225.

130. Matsuzaki M, Ogihara T, Umemoto S, et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29:1649-59.

131. MacDonald TM, Williams B, Webb DJ, et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc. 2017;6:e006986.

132. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124-31.

133. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010;28:1584-90.

134. Garjon J, Saiz LC, Azparren A, et al. First‐line combination therapy versus first‐line monotherapy for primary hypertension. Cochrane Database Syst Rev. 2017 Jan 13;1:CD010316. doi:10.1002/14651858.CD010316.pub2.

135. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32:649-64.

136. Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K, et al. The benefits of angiotensinconverting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. Int Urol Nephrol. 2018 Dec;50(12):2261-78. doi:10.1007/s11255-018-1991-x.

137. Williams B, MacDonald TM, Morant S, et al. British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, doubleblind, crossover trial. Lancet. 2015;386:2059-68.

138. Carey RM, Calhoun DA, Bakris GL. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov;72(5):e53-e90.

139. Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013 Jan 28;346:f360. doi:10.1136/bmj.f360.

140. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure–lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens 2015;33:1321–41.

141. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23:2113-8.

142. Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin–converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282-9.

143. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens. 2016;34:1921-32.

144. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611-21.

145. Fried LF, Emanuele N, Zhang JH, et al. NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-903.

146. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.

147. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens. 2015;33:195-211.

148. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly–treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-24.

149. Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136-47.

150. Rimoldi SF, Messerli FH, Chavez P, et al. Efficacy and safety of calcium channel blocker/ diuretics combination therapy in hypertensive patients: a meta‐analysis. J Clin Hypertens (Greenwich). 2015 Mar;17(3):193-9. doi:10.1111/jch.12462.

151. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar;122(3):290-300. doi:10.1016/j.amjmed.2008.09.038.

152. Kang S, Wu YF, An N, Ren M. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril–indapamide combination as first-line treatment of hypertension. Clin Ther. 2004 Feb;26(2):257-70.

153. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet. 2010 Mar 13;375(9718):906-15. doi:10.1016/S01406736(10)60235-8.

154. Chazova IE, Mychka VB. New opportunities in the treatment of patients with metabolic syndrome: results of the ALMAZ study. Systemic hypertension. 2006;2:14-7. (In Russ.)

155. Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Int J Hypertens. 2013;2013:541689. doi:10.1155/2013/541689.

156. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Current medical research and opinion. 2004;20,3:359-67.

157. Bhatt DL, Kandzari DE, O’Neill WW, et al. for the Symplicity HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-401.

158. Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressurebased trial. J Hypertens. 2016;34:1639-47.

159. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633-R641.

160. Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European Clinical Consensus Conference for Renal Denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219-27.

161. Narkiewicz K, Ratcliffe LE, Hart EC, et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci. 2016;1:313-24.

162. Bohm M, Mahfoud F, Ukena C et al. GSR Investigators. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65:766-74.

163. Ng FL, Saxena M, Mahfoud F, et al. Device–based therapy for hypertension. Curr Hypertens Rep. 2016;18:61.

164. Burchell AE, Lobo MD, Sulke N, et al. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension. 2014;64:6-12.

165. Kario K, Tomitani N, Kanegae H, et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring — The NOCTURNE Study. Circulation Journal. 2017;81;7:948-57.

166. Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:792-9.

167. Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-52.

168. Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end–stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64:588-97.

169. Bakris GL, Sarafidis PA, Weir MR, et al. ACCOMPLISH Trial Investigators. Renal outcomes with different fixed–dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-81.

170. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43.

171. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

172. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.

173. Emdin CA, Callender T, Cao J, et al. Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. The American journal of cardiology. 2015;116(1):155-61. doi:10.1016/j.amjcard.2015.03.052.

174. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur heart J. 2010;32(6):670-9.

175. Nanayakkara S, Kaye DM. Management of heart failure with preserved ejection fraction: a review. Clinical therapeutics. 2015;37(10):2186-98.

176. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73-90. doi:10.1161/CIRCULATIONAHA.116.021884.

177. Shah RV, Akshay SD, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Journal of cardiac failure. 2010;16(3):260-7.

178. Soliman EZ, Ambrosius WT, Cushman WC, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017:136(5):440-50.

179. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. The American journal of medicine. 2003 Jul;115(1):41-6.

180. Dahlof B, Kjell P, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. 1992:95-110.

181. Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on. Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart. Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion. Cardiaca y Electrofisiologia (SOLEACE). Europace. 2017;19:891-911.

182. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-962.

183. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Annals of internal medicine. 1999;131:492501;536,556.

184. Atrial fibrillation and flutter in adults. Clinical recommendations. All-Russian scientific society of specialists in clinical electrophysiology, Arrhythmology and electrical stimulation. Society of emergency cardiology specialists. 2016. (In Russ.) http://webmed.irkutsk.ru/doc/pdf/fedaf.pdf

185. Arima H, Chalmers J, Woodward M, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201-8.

186. Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20:1277-83.

187. Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement intracerebral hemorrhage study. Stroke. 2013;44:1846-51.

188. Anderson CS, Heeley E, Huang Y, et al. INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-65.

189. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-43.

190. Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology. 2014;83:1523-9.

191. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke. 2014;9:840-55.

192. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:2032-60. doi:10.1161/STR.0000000000000069.

193. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e138.

194. Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. Stroke. 2015;46:1883-9.

195. Zhao R, Liu FD, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve shortor long-term dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore). 2015;94:e896.

196. Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke — International Stroke Thrombolysis Register (SITS–ISTR). Stroke. 2009;40:2442-9.

197. WuW, HuoX, ZhaoX, et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS — China Study. PLoS One. 2016;11:e0144260.

198. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressurelowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet. 2001;358,9287:1033-41.

199. White CL, Szychowski JM, Pergola PE, et al. Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience. J Am Geriatr Soc. 2015;63:722-29.

200. SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. New England Journal of Medicine. 2015;373(22):2103-16.

201. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37,7:1933-40.

202. Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Cochrane database of systematic reviews. 2013;12.

203. Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. The Lancet. 2016;388(10056):2142-52.

204. Zanchetti A, Hennig M, Hollweck R et al. Baseline values but not treatment-induced changes incarotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009;120:1084-90.

205. Zanchetti A, Crepaldi G, Bond MG, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke. 2004;35:2807-12.

206. Myou S, Fujimura M, Kamio Y, et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med. 2000;162:40-4.

207. Chiu KY, Li JG, Lin Y. Calcium channel blockers for lung function improvement in asthma: A systematic review and meta-analysis. Ann Allergy Asthma Immunol 2017;119(6):518-23.e3.

208. Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensinconverting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12:263-77.

209. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.

210. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012;123(8):487-98.

211. Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation. 2001;104(3):281-5.

212. Sukmarova ZN, Litvin AYu, Chazova IE, Rogoza AN. Effectiveness of complex medication and CPAP therapy in patients with arterial hypertension of the 2nd-3rd degree and severe obstructive sleep apnea syndrome. Systemic hypertension. 2011;8(1):40. (In Russ.)

213. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on noncardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383-431.

214. Futier E, Lefrant JY, Guinot PG, et al. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. JAMA. 2017;318:1346-57.

215. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative betablockade with mortality and cardiovascular morbidity following major non-cardiac surgery. JAMA. 2013;309:1704-13.

216. Andersson C, Merie C, Jorgensen M, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwidecohort study. JAMA Intern Med. 2014;174:336-44.

217. Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta–blockers for preventing surgery–related mortality and morbidity. Cochrane Database Syst Rev. 2018;3:CD004476.

218. Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. Eur J Clin Pharmacol. 1979 Apr 17;15(3):215-7.

219. Gupta P, Patel P, Strauch B, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042-8.

220. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98-105.

221. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistanthypertension: results from a randomized trial. Hypertension. 2009;54:475-81.

222. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39:257-63.

223. Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25:1021-30.

224. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677-88.

225. Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593-9.

226. Grassi G, Seravalle G, Trevano FQ, et al. Neurogenic abnormalities in masked hypertension. Hypertension. 2007;50:537-42.

227. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378:1509-20.

228. Cuspidi C, Rescaldani M, Tadic M, et al. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a metaanalysis. J Hypertens. 2015;33:24-32.

229. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009;27:1672-8.

230. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159-69.

231. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-32.

232. Thakkar HV, Pope A, Anpalahan M. Masked Hypertension: A Systematic Review. Heart. Lung and Circulation. 2019.

233. Ogedegbe G, Agyemang C, Ravenell JE. Masked hypertension: evidence of the need to treat. Curr Hypertens Rep. 2010;12:349-55.

234. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. American journal of hypertension. 2011;24,1:52-8.

235. Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011 Jan;57(1):29-38. doi:10.1161/HYPERTENSIONAHA.110.160911.

236. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613-22.

237. Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. The Lancet. 2019;394,10203:1011-21.

238. Ogihara T, Saruta T, Rakugi H, et al.; COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res. 2015;38:89-96.

239. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14-effects of different classes of antihypertensive drugs in older and younger patients overview and meta-analysis. Journal of hypertension. 2018;36(8):1637-47.

240. Corrao G, Mazzola P, Monzio Compagnoni M, et al. Antihypertensive medications, loop diuretics, and risk of hip fracturein the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009. Drugs Aging. 2015;32:927-36.

241. Kjeldsen SE, Stenehjem A, Os I, et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press. 2016;25:333-6.

242. Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130(19):1692-9.

243. Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015;9(3):197-205.

244. Bavishi C, Goel S, Messerli FH. Isolated Systolic Hypertension: An Update After SPRINT Am J Med. 2016;129(12):1251-8.

245. Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009;53(3):458-65.

246. Li Y, Wei FF, Thijs L, et al. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466-74.

247. O’Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens. 2013;31:649-54.

248. Yano Y, Stamler J, Garside DB, et al. Isolated systolic hypertension in young and middleaged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol. 2015;65:327-35.

249. Penny JA, Halligan AW, Shennan AH, et al. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? Am J Obstet Gynecol. 1998;178:521-6.

250. Weitz C, Khouzami V, Maxwell K, Johnson JW. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. International Journal of Gynecology & Obstetrics. 1987;25,1:35-40.

251. Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood pressure. 2018;27,6:314-40.

252. Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception. 2006;73,2:179-88.

253. Lubianca JN, Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: an effective blood pressure–lowering intervention in women with hypertension. J Hum Hypertens. 2005;19:451-5.

254. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94:483-9.

255. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens. 1997;15:1063-8.

256. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72-8.

257. World Health Organization. Medical eligibility criteria for contraceptive use. Third edition, 2004. http://apps.who.int/iris/bitstream/10665/42907/1/9241562668.pdf (date accessed June 28th 2018).

258. La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry. 2015;48:1-6.

259. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens. 2004 Dec;17(12 Pt 1):1135-42.

260. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9:320-8.

261. Abi Aad S, Pierce M, Barmaimon G, et al. Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. Crit Rev Oncol Hematol. 2015;93:28-35.

262. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596-604.

263. Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. 2017;70:2552-65.

264. Milan A, Puglisi E, Ferrari L, et al. Arterial hypertension and cancer. Int J Cancer 2014;134:2269-77.

265. Sever PS, Dahlof B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.

266. Catapano AL, Graham I, De Backer G, et al. Authors/Task Force Members. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999-3058.

267. Fulcher J, O’Connell R, Voysey M, Emberson J, et al. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-405.

268. Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2011;12:CD003186.

269. van den Born BJ, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacotherapy 2018.

270. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411-7.

271. Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology. 1978;28:928-39.

272. van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24:2299-304.

273. Cremer A, Amraoui F, Lip GY, et al. From malignant hypertension to hypertensionMOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. 2016;30:463-6.

274. Pinna G, Pascale C, Fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One. 2014;9:e93542.

275. van den Born BJ, Lowenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29:922-7.

276. Grassi D, O’Flaherty M, Pellizzari M, et al. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich). 2008;10:662-7.

277. Grossman A, Messerli FH, Grossman E. Drug induced hypertension — An unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763:15-22.

278. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens. 2008;22:596-607.

279. Amraoui F, Van Der Hoeven NV, Van Valkengoed IG, et al. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich). 2014;16:122-6.

280. Gonzalez R, Morales E, Segura J, et al. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant. 2010;25:3266-272.

281. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta‐analysis. Journal of the American Heart Association. 2013;2,1:e004473.

282. Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-97.

283. Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885-8.

284. Viera AJ, Bangura F, Mitchell CM, et al. Do clinicians tell patients they have prehypertension? J Am Board Fam Med. 2011;24:117-8.

285. Gupta AK, McGlone M, Greenway FL, Johnson WD. Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile. Hypertens Res. 2010;33:905-10.

286. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913-22.

287. Bosworth HB, Olsen MK, Grubber JM, et al. Two self–management interventions to improve hypertension control: a randomized trial. Annals of internal medicine. 2009;151,10:687-95.

288. Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ.2004;328:204.

289. Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract. 2005;55,520:875-82.

290. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane database of systematic reviews. 2010;3.

291. Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455-68.

292. Duan Y, Xie Z, Dong F, et al. Effectiveness of home blood pressure telemonitoring: a systematic review and meta-analysis of randomised controlled studies. J Hum Hypertens. 2017;31:427-37.

293. Omboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17:535.

294. Bray EP, Holder R, Mant J, McManus RJ. Does self–monitoring reduce bloodpressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med 2010;42:371-86.

295. Niiranen TJ, Hanninen MR, Johansson J, et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office bloodpressure: the Finn–Home study. Hypertension. 2010;55:1346-51.

296. Dispensary observation of patients with chronic non-infectious diseases and patients with a high risk of their development. Methodical recommendation. Edited by S. A. Boytsov and A. G. Chuchalin. Moscow: 2014. 112 p. (In Russ.) URL: http://www.gnicpm.ru , http://www.ropniz.ru

297. Vanezis AP, Bhopal R. Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. Journal of Electrocardiology. 2008;41(5):404-12. doi:10.1016/j.jelectrocard.2008.02.013.

298. Jahromi AS, Cina CS, Liu Y, Clase CM. Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. Journal of vascular surgery. 2005;41,6:962-72.

299. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 — Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922-44.

300. Kelley GA, Kelley KA, Vu Tran Z. Aerobic exercise and resting blood pressure: a metaanalytic review of randomized, controlled trials. Preventive cardiology. 2001;4,2:73-80.

301. Semlitsch T, Jeitler K, Hemkens LG, et al. Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis. Sports medicine. 2013;43,10:1009-23.

302. Clinical recommendations. Algorithms for specialized medical care for patients with diabetes mellitus. Ed. I. I. Dedov, M. V. Shestakova, A. Yu. Mayorov, 9 issue, supplemented. Moscow 2019. (In Russ.)